Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MACROGENICS INCMGNX · Entity 6104 | Sr VP, Technical Ops | February 12, 2026 | February 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MACROGENICS INC
Report date February 12, 2026 · Filed February 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,543 |
Ending reported balance
After 2026-02-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-15 · Exercise / conversion · Acquired 13,332 · Balance 44,063 F1: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. Row 2 · 2026-02-15 · Tax withholding · Disposed 5,520 · Balance 38,543 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-15 · Exercise / conversion · Disposed 13,332 · Balance 0 F1: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 25,000 |
Reported balance
After 2026-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-12 · Grant · Acquired 25,000 · Balance 25,000 F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2036-02-12 | Direct | 150,000 |
Reported balance
After 2026-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-12 · Grant · Acquired 150,000 · Balance 150,000 F3: 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis.
F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.
F3: 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2026 Filed Feb 17, 2026 23:24 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 13,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001675464-26-000004 · wk-form4_1771370660.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,332 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2026 Filed Feb 17, 2026 23:24 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 5,520 | $1.71 | $9,439.20 |
DisclosureSEC source: 0001675464-26-000004 · wk-form4_1771370660.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,543 Read SEC document |
| February 15, 2026 Filed Feb 17, 2026 23:24 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 13,332 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001675464-26-000004 · wk-form4_1771370660.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 23:24 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001675464-26-000004 · wk-form4_1771370660.xml · derivative · entry 5 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-02-12 F3 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 23:24 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001675464-26-000004 · wk-form4_1771370660.xml · derivative · entry 4 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 08, 2026 Filed Feb 10, 2026 23:16 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 8,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001675464-26-000002 · wk-form4_1770765401.xml · derivative · entry 6 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 8,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into the Company's stock on a one-for-one basis. F3 · derivative.exercise_date: On February 8, 2024, the reporting person was granted 27,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On February 8, 2024, the reporting person was granted 27,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date. Read SEC document |
| February 08, 2026 Filed Feb 10, 2026 23:16 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 3,186 | $1.81 | $5,766.66 |
DisclosureSEC source: 0001675464-26-000002 · wk-form4_1770765401.xml · nonDerivative · entry 4 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,731 Read SEC document |
| February 08, 2026 Filed Feb 10, 2026 23:16 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 8,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001675464-26-000002 · wk-form4_1770765401.xml · nonDerivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 23:16 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 6,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001675464-26-000002 · wk-form4_1770765401.xml · derivative · entry 5 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,999 Underlying: Common Stock · 6,001 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into the Company's stock on a one-for-one basis. F2 · derivative.exercise_date: On February 7, 2025, the reporting person was granted 18,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On February 7, 2025, the reporting person was granted 18,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 23:16 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 2,485 | $1.81 | $4,497.85 |
DisclosureSEC source: 0001675464-26-000002 · wk-form4_1770765401.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,918 Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 23:16 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 6,001 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001675464-26-000002 · wk-form4_1770765401.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:15 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001675464-25-000003 · wk-form4_1755634501.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-08-15 F1 · derivative.exercise_date: 25% of the options will vest and became exercisable one year after the grant date and the remaining 75% will vest in 12 substantially equal quarterly installments thereafter. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:22 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 13,332 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000030 · wk-form4_1740000120.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,332 Underlying: Common Stock · 13,332 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:22 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 5,520 | $2.56 | $14,131.20 |
DisclosureSEC source: 0001125345-25-000030 · wk-form4_1740000120.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,402 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:22 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 13,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000030 · wk-form4_1740000120.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 01:20 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 9,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000013 · wk-form4_1739323240.xml · derivative · entry 5 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,999 Underlying: Common Stock · 9,001 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 8, 2024 the reporting person was granted 27,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 8, 2024 the reporting person was granted 27,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 8, 2024 the reporting person was granted 27,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 01:20 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 3,727 | $2.60 | $9,690.20 |
DisclosureSEC source: 0001125345-25-000013 · wk-form4_1739323240.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,590 Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 01:20 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 9,001 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001125345-25-000013 · wk-form4_1739323240.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 8, 2024 the reporting person was granted 27,000 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 01:20 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000013 · wk-form4_1739323240.xml · derivative · entry 4 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 01:20 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001125345-25-000013 · wk-form4_1739323240.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2035-02-07 F2 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:19 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001125345-24-000055 · wk-form4_1709759960.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 10,000 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:19 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 10,000 | $20.00 | $200,000.00 |
DisclosureSEC source: 0001125345-24-000055 · wk-form4_1709759960.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,316 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/17/2023. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:19 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 10,000 | $11.50 | $115,000.00 |
DisclosureSEC source: 0001125345-24-000055 · wk-form4_1709759960.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:03 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 13,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000036 · wk-form4_1708470220.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,664 Underlying: Common Stock · 13,336 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:03 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 5,020 | $17.40 | $87,348.00 |
DisclosureSEC source: 0001125345-24-000036 · wk-form4_1708470220.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,316 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:03 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 13,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000036 · wk-form4_1708470220.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 15, 2023 the reporting person was granted 40,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:32 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000023 · wk-form4_1707777154.xml · derivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:32 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 71,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001125345-24-000023 · wk-form4_1707777154.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 71,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:31 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 40,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-23-000036 · wf-form4_167666944263121.xml · derivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:31 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 170,000 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001125345-23-000036 · wf-form4_167666944263121.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 00:49 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 140,000 | $0.00 Strike: $10.15 | $0.00 |
DisclosureSEC source: 0001125345-22-000032 · wf-form4_164575011929211.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 21:09 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 5,000 | $7.51 Strike: $7.51 | $37,550.00 |
DisclosureSEC source: 0001125345-21-000092 · wf-form4_162681532070844.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,147 Underlying: Common Stock · 5,000 shares Expires 2023-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 12.5% of the shares underlying the grant become (or became) exercisable on the date reflected and an additional 6.25% of the shares underlying the grant become (or became) exercisable on the first day of each three-month period thereafter. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 21:09 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 5,000 | $25.01 | $125,050.00 |
DisclosureSEC source: 0001125345-21-000092 · wf-form4_162681532070844.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.04. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 21:09 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 5,000 | $7.51 | $37,550.00 |
DisclosureSEC source: 0001125345-21-000092 · wf-form4_162681532070844.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 22:37 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 5,000 | $7.51 Strike: $7.51 | $37,550.00 |
DisclosureSEC source: 0001125345-21-000054 · wf-form4_161887184277337.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,147 Underlying: Common Stock · 5,000 shares Expires 2023-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 12.5% of the shares underlying the grant become (or became) exercisable on the date reflected and an additional 6.25% of the shares underlying the grant become (or became) exercisable on the first day of each three-month period thereafter. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 22:37 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 5,000 | $30.91 | $154,550.00 |
DisclosureSEC source: 0001125345-21-000054 · wf-form4_161887184277337.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.71 to $31.20. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 22:37 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 5,000 | $7.51 | $37,550.00 |
DisclosureSEC source: 0001125345-21-000054 · wf-form4_161887184277337.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:04 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 95,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000029 · wf-form4_161420786944480.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 20:05 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 7,500 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001125345-20-000129 · wf-form4_159804028658626.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,147 Underlying: Common Stock · 7,500 shares Expires 2023-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 12.5% of the shares underlying the grant become (or became) exercisable on the date reflected and an additional 6.25% of the shares underlying the grant become (or became) exercisable on the first day of each three-month period thereafter. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 20:05 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 7,500 | $26.87 | $201,525.00 |
DisclosureSEC source: 0001125345-20-000129 · wf-form4_159804028658626.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.54 to $27.27. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staffof the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 20:05 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 7,500 | $7.51 | $56,325.00 |
DisclosureSEC source: 0001125345-20-000129 · wf-form4_159804028658626.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2020 Filed May 21, 2020 23:44 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 7,500 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001125345-20-000098 · wf-form4_159010466198723.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,647 Underlying: Common Stock · 7,500 shares Expires 2023-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable on the date reflected and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. Read SEC document |
| May 20, 2020 Filed May 21, 2020 23:44 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 7,500 | $25.30 | $189,750.00 |
DisclosureSEC source: 0001125345-20-000098 · wf-form4_159010466198723.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.86 to $25.78. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2020 Filed May 21, 2020 23:44 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 7,500 | $7.51 | $56,325.00 |
DisclosureSEC source: 0001125345-20-000098 · wf-form4_159010466198723.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:45 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 87,000 | $11.50 Strike: $11.50 | $1,000,500.00 |
DisclosureSEC source: 0001125345-20-000020 · wf-form4_158258068883545.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,000 Underlying: Common Stock · 87,000 shares Expires 2030-02-20 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 21:03 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $21.88 | $0.00 |
DisclosureSEC source: 0001125345-19-000033 · wf-form4_155112857112121.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-21 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:40 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 1,770 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001125345-19-000016 · wf-form4_154966559772237.xml · derivative · entry 3 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,147 Underlying: Common Stock · 1,770 shares Expires 2023-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:40 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 1,770 | $30.00 | $53,100.00 |
DisclosureSEC source: 0001125345-19-000016 · wf-form4_154966559772237.xml · nonDerivative · entry 2 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2018. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:40 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 1,770 | $7.51 | $13,292.70 |
DisclosureSEC source: 0001125345-19-000016 · wf-form4_154966559772237.xml · nonDerivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 22:23 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $28.94 | $0.00 |
DisclosureSEC source: 0001125345-18-000041 · wf-form4_152037497145731.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-03-02 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.